Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SIRIUS - A Prospective, Non-randomized, Open-label, Proof-of-concept Study of Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension A Single-arm, Multi-center, Interventional Phase II Study

NCT07266519 is registered in ClinicalTrials.gov with Philipps University Marburg as lead sponsor.

NCT NCT07266519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07266519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SIRIUS - A Prospective, Non-randomized, Open-label, Proof-of-concept Study of Initial Combination Therapy With an Endothelin Receptor Antagonist, a Phosphodiesterase-5 Inhibitor and Sotatercept in Patients With Newly Diagnosed Pulmonary Arterial Hypertension A Single-arm, Multi-center, Interventional Phase II Study
Lead sponsor
Philipps University Marburg
Phase
Phase 2
Overall status
Not yet recruiting
Start date
July 1, 2026
Completion date
October 31, 2028
Enrollment
25 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension (pah)